Sanofi-Genzyme Deal Unchanged

FOXBusiness

Drugmaker Sanofi-Aventis (NYSE:SNY) said on Friday that its position on the Genzyme (NASDAQ:GENZ) takeover has not changed since last Sunday, when the French company made an offer to purchase Genzyme.

The two companies announced this week that they are in talks for a takeover, which would include a cash component of around $70 to $71 with a contingent value right, according to a Reuters report.

Continue Reading Below

On Friday, Sanofi confirmed that two patients taking its Multaq heart drug experienced liver failure, but did not say there was a link. The U.S. Food and Drug Administration issued a drug safety notice on the subject even without the cause proven.

What do you think?

Click the button below to comment on this article.